Abstract
Metastatic disease is the main cause of breast cancer-related deaths. Given advances in the molecular profiling of tumors, we here aimed at integrating proteome, phosphoproteome and transcriptome data for the profiling of primary tumors to allow for discovery of new subtypes and features predicting lymph node and distant metastases in breast cancer (BC). We analyzed a total of 182 estrogen-receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative BC samples using label-free Data Independent Acquisition (DIA) liquid chromatography tandem mass spectrometry (LC-MS/MS), quantifying a total of 13571 protein groups, 7107 phosphopeptides and 13085 expressed genes in at least 70% of the samples. Unsupervised consensus cluster analyses permitted the identification of potential subtypes with differential immune infiltration pattern and survival. Immune deconvolution data was combined with multiomics factor analysis, providing unique insight into different markers for lymph node and distant metastases. In summary, we further developed a protocol for parallel acquisition of matched proteomics, phosphoproteomics and transcriptomics data, resulting in the most comprehensive dataset of its kind and allowing for unique insights into metastatic processes in ER-positive/HER2-negative BC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by the Erling Persson Foundation and the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 754299 (EU-H2020-MSCA-COFUND-754299-CanFaster).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Included patients were enrolled in the Sweden Cancerome Analysis Network - Breast (SCAN-B) study (ClinicalTrials.gov ID NCT02306096) (PMID:25722745,29341157) approved by the Regional Ethical Review Board in Lund, Sweden (registration numbers 2009/658, 2010/383, 2012/58, 2013/459, 2014/521, 2015/277, 2016/541, 2016/742, 2016/944, 2018/267 and the Swedish Ethical Review Authority (registration numbers 2019-01252, 2024-02040-02).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.